Madrigal Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
MDGL Nasdaq 2830 www.madrigalpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Madrigal Pharmaceuticals, Inc.

3 late-stage MASH drugs that could rival Rezdiffra - Jun 29th, 2026 3:00 am
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Jun 22nd, 2026 2:05 pm
3 Under-the-Radar Stocks to Buy and Hold for a Decade - Jun 16th, 2026 1:50 am
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release - Jun 9th, 2026 12:14 am
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound? - Jun 5th, 2026 9:30 am
Madrigal (MDGL) Data Highlights Rezdiffra’s Cardiometabolic Benefits for MASH Patients at EASL Congress - Jun 4th, 2026 3:07 am
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 - Jun 3rd, 2026 6:00 am
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness - Jun 2nd, 2026 4:08 pm
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% - May 29th, 2026 6:47 pm
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More - May 29th, 2026 6:41 pm
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH - May 27th, 2026 6:00 am
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk - May 20th, 2026 6:00 am
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales Growth - May 10th, 2026 1:08 pm
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up - May 7th, 2026 9:35 am
Madrigal Pharmaceuticals Q1 Earnings Call Highlights - May 6th, 2026 1:44 pm
Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - May 6th, 2026 10:57 am
Madrigal (MDGL) Q1 2026 Earnings Transcript - May 6th, 2026 10:15 am
Madrigal’s (MDGL) MASH Strategy Reiinforced By Rezdiffra Sales Growth and Pipeline Expansion - May 6th, 2026 8:46 am
Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates - May 6th, 2026 6:25 am
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates - May 6th, 2026 5:00 am